The monoclonal antibody trastuzumab (Herceptin) is an anti-HER2 antibody that has resulted in an extension of lifespan for breast cancer patients, and has been approved for treatment of gastric carcinomas that overexpress HER2. Here, ERBB2 is linked to breast carcinoma.